Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
BB Biotech ( (CH:BION) ) has shared an announcement.
BB Biotech AG has released its interim report for the first quarter of 2025, revealing a loss of CHF 241 million, a significant shift from the CHF 260 million profit recorded in the same period last year. This loss reflects the stock price development of the companies within its investment portfolio, indicating potential challenges in the biotech investment landscape.
More about BB Biotech
BB Biotech AG is an investment company based in Schaffhausen, Switzerland, and is listed on the Swiss and German stock exchanges. Since 1993, it has focused on investing in innovative drug development companies, primarily in the USA and Western Europe, positioning itself as a leading investor in this sector. The company relies on the expertise of its board of directors and the investment management team of Bellevue Asset Management AG for strategic investment decisions.
YTD Price Performance: -15.02%
Average Trading Volume: 2,703
Technical Sentiment Signal: Buy
Current Market Cap: CHF1.49B
For an in-depth examination of BION stock, go to TipRanks’ Stock Analysis page.